PuSH - Publikationsserver des Helmholtz Zentrums München

Novikoff, A. ; Müller, T.D.

SURMOUNTing body weight barriers in type 2 diabetes.

Med. 4, 849-851 (2023)
DOI PMC
The emergence of GIPR:GLP-1R co-agonists has heralded a renaissance of anti-obesity medication. In the recent SURMOUNT 2 trial, Garvey and colleagues set out to examine the weight loss efficacy of the GIPR:GLP-1R co-agonist tirzepatide in patients with obesity and type 2 diabetes, reporting that tirzepatide has unprecedented efficacy in a magnitude historically considered almost unattainable.1.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Editorial
Korrespondenzautor
Schlagwörter Obesity
ISSN (print) / ISBN 2666-6359
e-ISSN 2666-6340
Zeitschrift Med (N Y)
Quellenangaben Band: 4, Heft: 12, Seiten: 849-851 Artikelnummer: , Supplement: ,
Verlag Cell Press
Verlagsort 50 Hampshire St, Floor 5, Cambridge, Ma 02139 Usa
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
Förderungen German Center for Diabetes Research (DZD e.V.)
German Research Foundation (DFG)
European Research Council ERC-CoG Trusted